Multi-omics characterization identifies AHCY as a prognostic biomarker driving immunometabolic reprogramming in bladder cancer
Our findings identify AHCY as a prognostic biomarker and immunometabolic regulator in BLCA, linking methionine metabolism to tumor progression, immune suppression, and drug resistance. AHCY holds promise as a therapeutic target and companion biomarker for precision oncology.
Authors
- Bo Su (ORCID: https://orcid.org/0000-0003-4148-1202)
- Donghui Shi (ORCID: https://orcid.org/0000-0001-5301-368X)
- Mengmei Zhang (ORCID: https://orcid.org/0000-0002-4581-0977)
- Ziyou Lin (ORCID: https://orcid.org/0000-0002-3657-5004)
- Mengjie Shan (ORCID: https://orcid.org/0000-0002-3451-1103)
- Shuyu Zhao (ORCID: https://orcid.org/0000-0002-2271-3269)
- Yadong Guo (ORCID: https://orcid.org/0000-0001-7468-8061)
- Shiyu Mao (ORCID: https://orcid.org/0000-0003-4652-6828)
- Qiao Peng (ORCID: https://orcid.org/0000-0002-5632-3090)
Institutions
- Tongji University (CN)
- Shanghai Tenth People's Hospital (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1016/j.tranon.2025.102652
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00